HR+/HER2 Breast Cancer

AUG 19, 2026 · PHASE 3 TRIAL

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

ClinicalTrials.gov

This is an active Phase 3 trial registration with no results posted; the study is still recruiting and outcomes are not yet reported.

AUG 19, 2026 · PHASE 2 TRIAL

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

ClinicalTrials.gov

Phase 2 neoadjuvant trial of an investigational PD-L1 inhibitor combined with chemotherapy in early HR+/HER2- breast cancer; no results reported in this registry record.

AUG 10, 2026 · PHASE 1/2 TRIAL

ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

ClinicalTrials.gov

This is a Phase 1/2 first-in-human trial registration with no results posted; it describes planned safety, tolerability, and dose-finding work in a new CDK4 inhibitor.

AUG 7, 2026 · PHASE 3 TRIAL

Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC

ClinicalTrials.gov

This is a Phase 3 trial registration with no posted results; the study is actively recruiting and has not yet generated outcome data.

JUL 31, 2026 · PHASE 3 TRIAL

Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests

ClinicalTrials.gov

This is an active Phase 3 RCT registration with no posted results; the study is recruiting and outcome data are not yet available, making any efficacy claim impossible.